<DOC>
	<DOCNO>NCT02945020</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state concentration odalasvir ( ODV ) , single agent combination simeprevir ( SMV ) , single-dose pharmacokinetics dabigatran etexilate healthy participant .</brief_summary>
	<brief_title>A Pharmacokinetic Interaction Study Between Odalasvir , Given Single Agent Combination With Simeprevir , Dabigatran Etexilate Mesylate Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Participant must body mass index ( BMI : weight kilogram [ kg ] divide square height meter ) 18.0 32.0 kilogram per square meter ( kg/m^2 ) , extremes include , body weight less 50.0 kg Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen . If abnormality , participant may include Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document initial Investigator Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic . If blood pressure range , 2 repeat assessment permit Female participant , except postmenopausal , must negative highly sensitive serum beta human chorionic gonadotropin screen Participant must nonsmoker least 6 month prior first study drug administration Participant history liver renal insufficiency ( estimate creatinine clearance 90 milliliter per minute ( mL/min ) calculate use CockcroftGault formula 90 mL/min/1.73 square meter ( m^2 ) estimate glomerular filtration rate [ eGFR ] accord Chronic Kidney Disease Epidemiology Collaboration equation [ CKDEPI ] ) , significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Participant condition , opinion Investigator , participation would best interest particiapant ( eg , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant known allergy , hypersensitivity , intolerance odalasvir ( ODV ) , simeprevir ( SMV ) dabigatran etexilate mesylate excipients Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV screen</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>